nLIGHT (LASR) Q1 2026 Earnings Transcript

nLIGHT posted a strong Q1 with revenue up 55% year over year to $80.2 million, product gross margin hitting a record 43.6%, and adjusted EBITDA reaching a quarterly record of $13.9 million. Management launched the Hades scalable high-energy laser platform and said the company is on track for HELSI 2 while benefiting from nearly $400 million in directed-energy budget visibility in FY2027-2028. Q2 guidance calls for $75 million-$81 million in revenue and $8 million-$12 million in adjusted EBITDA, while the company said it is not currently capacity constrained and has about $333 million in cash.

Analysis

LASR is transitioning from a cyclical component supplier into a defense-enablement platform story, and that matters more than the headline revenue beat. The launch of Hades plus the emphasis on system-level integration suggests the addressable market is no longer limited to selling lasers into fixed programs; it can now attach to platform upgrades, retrofit cycles, and follow-on content, which typically creates a longer revenue tail and better pricing power. The second-order effect is that margins can stay structurally higher if management keeps winning higher-value integration slots rather than just source shipments.

The bigger inflection is balance sheet optionality. The equity raise looks dilutive on the surface, but it de-risks execution at exactly the moment defense budget signal is improving and new capacity is being added ahead of demand; that combination often precedes a rerating because investors stop assigning “one-program” risk. Longmont also functions as a call option on multi-year awards: if awards slip, the cash just becomes idle balance sheet; if awards accelerate, the company can capture share before peers can retool capacity.

Near term, the company is guiding conservatively enough that consensus probably underestimates operating leverage if product mix holds and industrial exits do not create a larger-than-expected revenue hole. The real risk is not demand, but timing: appropriations drift, prototype funding can slip by quarters, and the 2Q margin reset implies some normalization after an unusually strong mix quarter. If Hades wins are more incremental than transformative, the stock could stall despite strong fundamentals because the market will have already priced in a “platform” multiple.

Contrarian takeaway: the cleanest bull case is not defense demand alone, but the convergence of defense budget visibility, manufacturing capacity expansion, and a shrinking low-margin legacy business. That is usually when gross margin expands faster than revenue in the next 2-4 quarters, creating a surprise to both estimates and sentiment. The market may still be underappreciating how quickly LASR can re-rate once investors believe the company has escaped the commodity-laser narrative.

Key Decisions for Investors

• Go long LASR on pullbacks over the next 1-3 weeks; target a 6-9 month hold. Risk/reward is attractive if the market is still valuing it as a component supplier rather than a defense platform, with upside from multiple expansion if Hades converts into awards.
• Use a call spread in LASR rather than outright stock for the next 3-6 months: buy the 6-12 month call and sell a higher strike to express the view that defense catalysts re-rate the name before full budget realization. This caps theta bleed if Congress delays.
• Pair trade: long LASR / short a diversified industrial laser or optics peer with less defense exposure over 3-6 months. The trade benefits if defense mix and margin leverage remain the dominant earnings driver while legacy commercial revenue rolls off.
• If already long, hedge event risk with a short-dated collar into the next budget update or award window. The key downside is timing slippage, not business deterioration, so protect against a 10-15% pullback on delayed appropriations.
• Monitor for a follow-on contract announcement or Longmont capacity update; if both appear within the next 1-2 quarters, add on confirmation rather than pre-emptively, as the stock can move sharply on hard program evidence.